D-0743-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0743-2021 was initiated by Teva Pharmaceuticals USA on Jul 29, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 50,713 vials.

Recall details

Product Type
Drugs
Report Date
Aug 25, 2021
Initiation Date
Jul 29, 2021
Termination Date
Jun 4, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
50,713 vials

Product description

Methylprednisolone Acetate Injectable Suspension USP, 80 mg/mL, packaged in a) 1 mL Single-Dose vials (0703-0051-01), and b) 5mL Multi Dose Vials (NDC 0703-0063-01), Rx only, TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454.

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Product was distributed Nationwide, including Puerto Rico.

Code information

Lot #: a) 31329363B, exp. date 01/2022; 31329484B, exp. date 03/2022 b) 31328367B, 31328431B, exp. date 07/2021; 31329014B, exp. date 11/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0743-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0743-2021. Report a data issue: hello@regdatalab.com.